The delivery of candidate antigens as heterologous prime/boost vaccine [13,27,28] provided protective immunity consisting of parasite- and antigen-specific lytic antibodies and type 1 CD8+ cytotoxic T lymphocytes against challenge infection and chronic disease that was significantly better than that observed with DNA-prime/DNA-boost vaccine [10,11]. Here, CD8A is linked to infection.